Form 4: Edwards Lifesciences Executive Larry L. Wood Reports Stock Transactions

Larry L. Wood, Global President TAVR & Surg at Edwards Lifesciences, reports stock transactions including the vesting of performance rights and associated tax withholding.

Summary

• On May 3, 2024, Larry L. Wood disposed of 395 shares of Edwards Lifesciences common stock at a price of $85.06 per share to cover tax obligations.
• On May 4, 2024, 6,675 performance rights vested, resulting in the acquisition of 6,675 shares of common stock.
• Also on May 4, 2024, 3,541 shares were disposed of at $85.25 per share for tax withholding related to the vesting of performance rights.
• Following these transactions, Wood directly owns 216,480.739 shares of common stock and indirectly owns 495.8781 shares through a 401(k) plan.
• The performance rights were granted on May 4, 2021, and vested based on the Compensation and Governance Committee's determination that 117.11% of the target number of shares would vest.

Sentiment

Score: 7

Explanation: The document reflects standard executive compensation practices and stock transactions, with the vesting of performance rights suggesting positive performance. The sentiment is neutral to slightly positive.

Positives

• The vesting of performance rights indicates that performance goals were met, leading to the acquisition of 6,675 shares.

Industry Context

Executive stock transactions are a common occurrence in publicly traded companies and are closely monitored by investors for insights into management's perspective on the company's performance and future prospects.

Comparison to Industry Standards

• Executive compensation packages often include performance-based equity awards, such as the performance rights granted to Larry L. Wood, to align management's interests with those of shareholders.
• The vesting of these awards is typically tied to the achievement of specific financial or operational targets, as determined by the company's compensation committee.
• Tax withholding related to the vesting of equity awards is a standard practice, and the number of shares disposed of for this purpose is generally proportional to the value of the vested shares and the applicable tax rates.
• Comparing Edwards Lifesciences' executive compensation practices to those of its peers, such as Medtronic, Abbott, and Boston Scientific, can provide insights into the company's approach to incentivizing and rewarding its executives.

Stakeholder Impact

• The vesting of performance rights and subsequent stock transactions may have a minor impact on shareholders, as it reflects the alignment of management's interests with the company's performance.
• Employees participating in the Employee Stock Purchase Plan are also stakeholders, as the Form 4 includes quarterly acquisition of shares under the plan.

Key Dates